
usd may pm et
summari lead develop manufactur provid analyt instrument
complex servic life scienc drug discoveri industri applic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr pm stock trade
revenu rose yoy driven
strong quarter laboratori product
servic lp life scienc ls
offset sharp declin
analyt busi ai flat
perform specialti diagnost despit
revenu loss yoy china
asia-pacif busi north america
europ remain resili late
enabl record organ growth
expect continu revenu declin
beyond asia-pacif region rest
year cut ep estim
line tmo revenu guidanc
rang rang flat
yoy declin expect low singl digit
declin sale due order
cancel delay global significantli
affect
yet start benefit certain
tailwind mainli relat
test expect amplifi rest
year due massiv demand
author use kit countri
follow suit led produc
test per week absorb demand
recommend buy view
solid long-term growth prospect
despit headwind stem
think dual strategi invest
heavili intern innov organ growth
pursu leverag scale
paid secur industry-lead
assort health care technolog one
supplier major competit advantag
moder leverag compar
peer net debt/ebitda
decemb expect go
post acquisit
total debt long-term
cash cover total short-term debt
target ep
estim line current ntm
result think justifi
becom higher growth margin play
highest-margin busi sale
risk view
includ slump end market particularli
biopharma cut prolong
slowdown global due
rel low cyclic sale due
geograph divers fragment custom base
well increas focu suppli reliabl
demand market like life scienc clinic
diagnost also benefit industry-lead
scale allow lower sourc product
cost peer view benefit balanc
risk technolog obsolesc frequent
develop cutting-edg technolog requir
remain relev intens competit market
give rise integr risk
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview thermo fisher scientif lead provid life scienc tool
servic broad array end market includ pharma biotech compani academ
govern institut diagnost health care compani industri appli scienc
compani tmo product servic includ laboratori analyt instrument biochem reagent
laboratori medic consum softwar servic research analysi discoveri
diagnosi think largest compani within marketplac broadest product offer
geograph coverag
busi segment life scienc solut sale provid reagent instrument
consum use biolog medic research discoveri product new drug
vaccin well diagnosi diseas life scienc solut includ four primari busi
bioscienc genet scienc clinic next-gener sequenc bioproduct analyt
instrument sale provid instrument consum softwar servic use
rang applic laboratori product line field segment includ three
primari busi chromatographi mass spectrometri chemic analysi materi
structur analysi specialti diagnost sale offer wide rang diagnost test kit
reagent cultur media instrument associ product custom health care clinic
pharmaceut industri food safeti laboratori specialti diagnost product gener use
increas speed accuraci diagnos improv qualiti cost-effect
patient care laboratori product servic sale laboratori supplier offer virtual
everyth need oper lab combin self-manufactur sourc product
segment also includ comprehens offer outsourc servic use biopharmaceut
firm drug develop clinic trial logist commerci drug manufactur
corpor strategi think tmo greatest strength lie industry-lead product breadth
across segment view creat one-stop shop effect allow research organ larg
small conveni order divers product need time cost-effect manner
one sourc exampl pharma custom start purchas mass spectromet
like eventu pitch sale rep save drug compani lab could
gener switch lab product supplier initi relationship may lead
provid manufactur servic compani downstream depart think
breadth tmo product servic help gain market share concentr competitor
way continu expand product portfolio extens intern develop
extern growth via acquisit tmo combin capital-expenditure roughli line
next three largest competitor combin calcul also proven extrem effect
streamlin oper acquir firm compani execut worth acquisit
sinc end steadili increas adjust pre-tax incom margin period
recent notabl acquisit includ brammer billion may advanc
bioprocess million octob expand tmo capabl suppli
rapidli grow biolog gene cell therapi market earlier invest includ august
acquisit patheon billion septemb acquisit fei compani billion
march acquisit affymetrix billion illustr tmo adept integr larg
acquisit note patheon ebita margin earn interest tax amort
stand-alon busi lower success achiev cost synergi target
overal ebita margin maintain august acquisit also see
strong revenu growth opportun patheon clinic trial servic bioproduct technolog
expect improv margin scale grow
competit landscap life scienc tool servic marketplac highli fragment
competit think may competit advantag peer due purchas
power oper leverag broad product offer geograph coverag publicli trade competitor
includ water corp among privat held
firm vwr corpor tmo primari competitor
impact major develop a- announc march acquisit
dutch provid life scienc molecular diagnost solut develop test kit detect
use china far expect deal expand tmo specialti diagnost
portfolio includ infecti diseas test particularli relev complement life
scienc offer aim gener synergi three year cost synergi
revenu find reason expect deal ep accret upon closur
first half
financi trend sale increas repres three-year
compound annual growth rate compound-annual-growth-rate prolif acquir acquisit aid
sale growth adjust earn per share rose repres compound-annual-growth-rate
estim ebita-to-interest coverag improv last
major acquisit patheon think repres return conserv
leverag level leav well-posit
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
life scienc tool servic sub-industri
expect earn growth remain
posit slow sharpli rate achiev
risk factor see slower
biopharmaceut spend growth
prolong uncertainti due
nation institut nih budget
grow rapidli last three
year materi increas fund
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih fy
sep budget grew vs prior year
follow growth fy
mark major acceler averag growth
fy fy believ
boost sale lst
sub-industri grew
prolifer advanc health care around
world continu drive demand growth
lst firm long-term emerg
market particularli china india
rapidli grow middl class gain
access advanc health care
drive suppli need new expand
medic research lab facil howev
due rapidli spread coronaviru
result suppli chain travel disrupt
expect slowdown demand next
think biopharmaceut firm moder
 spend growth due
outbreak
estim total spend
global biopharmaceut compani grew
annual averag expect slow
see
delay new clinic trial halt
on-go studi major pharmaceut
compani larg swath biopharma
typic flow lst firm suppli
depart research tool softwar
contract servic accordingli think
slowdown biopharma growth
reduc tailwind mani lst firm
receiv client group recent
expect recent coronaviru outbreak
oper result first half
china small promis market
lst compani around total
sector revenu seen number
disrupt due travel restrict
temporari closur site china
expect loss stem chines
oper limit expect
loss increas
time certain lst compani
well-posit benefit outbreak
close work
govern hospit develop test
kit sequenc genom viru
fda issu emerg author
number lst firm diagnost
serolog test use
laboratori detect
consider need respond grow
daili diagnost demand point
 lst compani quickli
absorb demand
year date april
servic declin compar
decreas experienc
broader healthcar sector
decreas overal
index life scienc tool
much faster rise
healthcar sector rise
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
pm et cfra maintain buy opinion share thermo fisher scientif
inc maintain price target ep estim
share major analyt instrument maker sharpli
today includ
around midday believ sell-off partial relat
ad chines firm export blacklist monday increas tension
trade war view hurt global suppli chain
instrument maker disagre reaction share howev
think compani global divers product facil uniqu lack
single-sourc suppli relationship give much greater flexibl peer
avoid tariff-driven cost increas view advantag actual allow
take signific instrument market share smaller firm like
etc reli china revenu wherea
gener roughli sale /colin scarola
et cfra maintain buy opinion share thermo fisher
scientif inc keep target ep
estim materi histor forward price-to-earnings averag expect
continu margin expans de-lever rais ep estim
ep vs
beat consensu organ revenu growth slow yoy
averag previou four quarter view
impress light econom growth slowdown sever intern
market year life scienc oper profit show sign
slow howev organ revenu growth yoy oper profit
growth yoy life scienc continu strength china sale
grew mid-teen yoy despit new tariff drove total oper profit
growth yoy adjust foreign exchang impact expect ep
grow strong demand outlook improv oper effici
ampl dri powder /colin scarola
analyst research note compani news
et cfra keep buy opinion share thermo fisher scientif
inc keep target ep estim
line tmo current ntm forward price-to-earnings follow better
expect result expect continu revenu declin beyond
asia-pacif region rest cut ep estim
also trim ep estim
ep vs consensu revenu came
slightli estim yoy despit revenu loss
china busi america europ remain strong late lab
product servic total life scienc revenu total
respect offset declin analyt
instrument total flat perform specialti diagnost
benefit certain tailwind relat
protect test research gener addit revenu growth
off-set part headwind caus shutdown china /sel
pm et cfra maintain buy opinion share thermo fisher
scientif inc keep target revis
ep estim cut ep estim
pencil risk slowdown china relat coronaviru stay
within tmo guidanc rang trim ep
estim point yoy increas ep
vs consensu revenu rose driven anoth
strong quarter life scienc yoy led bioproduct bioscienc
genet scienc off-set yoy declin analyt instrument
due strong base year slower releas fund china
yoy declin specialti diagnost due anatom patholog
divest valuat impli premium tmo histor forward
averag feel justifi becom higher growth margin
play success grew life scienc tmo highest margin busi
sale /sel hardi
pm et cfra maintain buy opinion share thermo fisher
scientif inc lift target
ep estim maintain ep estim lift
valuat well forward price-to-earnings
averag feel justifi move onto higher
growth margin plane specif invest expand life scienc
sale pay total organ sale
growth went averag remain
elev despit slow global growth life scienc also earn
highest margin vs averag segment lead
overal margin improv sinc see trend elev
growth margin continu long term aid expand cross-sel
capabl recent acquisit advanc bioprocess brammer
make leader suppli fast grow biolog gene cell
et cfra maintain buy opinion share thermo fisher
scientif inc keep target
ep estim histor forward price-to-earnings averag see continu
margin expans lift ep estim
start ep vs beat
consensu despit global econom slowdown tariff headwind
gener impress organ sale growth yoy adjust ep
grew even faster margin expans life scienc sale
continu primari driver organ sale yoy robust demand
pharma biotech client trade war notwithstand china sale
remain strong trajectori yoy remain favor
supplier nation rapidli expand health care sector think
strong earn market share gain face slow global growth
speak durabl product demand valu uniqu assort
healthcar technolog bring custom /colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
